Compare VHC & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VHC | NEPH |
|---|---|---|
| Founded | 2005 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Medical/Dental Instruments |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 46.0M | 49.4M |
| IPO Year | 2008 | 2004 |
| Metric | VHC | NEPH |
|---|---|---|
| Price | $11.57 | $4.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | ★ 74.3K | 31.4K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.99 | ★ 1000.00 |
| EPS | N/A | ★ 0.12 |
| Revenue | $162,000.00 | ★ $18,789,000.00 |
| Revenue This Year | N/A | $11.24 |
| Revenue Next Year | N/A | $11.58 |
| P/E Ratio | ★ N/A | $37.67 |
| Revenue Growth | ★ 3140.00 | 32.67 |
| 52 Week Low | $9.82 | $2.66 |
| 52 Week High | $29.00 | $6.42 |
| Indicator | VHC | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 41.95 | 56.64 |
| Support Level | $10.84 | $3.99 |
| Resistance Level | $18.44 | $4.70 |
| Average True Range (ATR) | 1.04 | 0.33 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 28.98 | 75.79 |
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. Its software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.